Europe
-
It could take years to develop a gene therapy to slow aging, but much less for big pharma to scoop up Genflow Biosciences -
Issuer sees little negative impact after ending tradition of publishing issuance windows
-
First CB of year receives 'decent' interest, yields minus 2.3%
-
Appointment is part of global plan to cross-sell investment banking services
-
Georgian telecoms company will woo US investors as it attempts to raise $300m
-
Tech names and spin-offs will dominate the German IPO market this year, with investors drawn to sustainable profits and size
-
Smaller order books but more asset managers expected beyond 10 year maturities
-
Debut green deal follows days after Aareal kicked off 2022 with covered bond
-
Demand at a range of maturities shows issuers just how many options are available
-
Bondholders consider ramifications of shock uprising for Turkey, Russia and beyond
-
Investor shift comes as ending Pepp and soaring volumes pressure spreads
-
The US asset manager has cut its stake in the Austrian bank from over 20% to 5% since September
